An individual patient-data meta-analysis of metronomic oral vinorelbine in metastatic non-small cell lung cancer

lEarly Clinical Studies Group ofEORTC, 2EORTCData Center, ^Pierre Fabre Oncology, ^Centre Oscar Lambret, Lille, France Summary

September 2016

Background: Vinorelbine is an active drug in the treatment of lung and breast cancers and has a favo...

A Randomized Phase II Trial of Single-Agent Gemcitabine, Vinorelbine, or Docetaxel in Patients with Advanced Non-small Cell Lung Cancer Who Have Poor Performance Status and/or Are Elderly

Leong, Swan Swan
Toh, Chee Keong
Lim, Wan Teck
Lin, Xu
Tan, Say Beng
Poon, Donald
Tay, Miah Hiang
Foo, Kian Fong
Ho, Juliana
Tan, Eng Huat

March 2007

Background:Patients with poor performance status and/or are elderly are frequently considered a comp...

Oral metronomic vinorelbine in advanced non-small cell lung cancer patients unfit for chemotherapy

Banna G. L.
Camerini A.
Bronte G.
Anile G.
Addeo A.
Rundo F.
Zanghi G.
Lal R.
Libra M.

January 2018

Aim: To explore the feasibility and activity of oral metronomic vinorelbine patients with advanced N...

Metronomic oral vinorelbine for the treatment of advanced non-small cell lung cancer. a multicenter international retrospective analysis

Camerini A.
Banna G. L.
Cinieri S.
Pezzuto A.
Mencoboni M.
Rosetti F.
Figueiredo A.
Rizzo P.
Ricci A.
Langenhoven L.
Santo A.
Addeo A.
Amoroso D.
Barata F.

January 2019

Purpose: Metronomic oral vinorelbine (MOV) could be a treatment option for unfit patients with advan...

Metronomic Oral Vinorelbine: An Alternative Schedule in Elderly and Patients PS2 With Local/Advanced and Metastatic NSCLC Not Oncogene-addicted

Rossi, David
Lippe, Paolo
Rocchi, Marco Bruno Luigi
Sarti, Donatella
Catalano, Vincenzo
Graziano, Francesco
Giordani, Paolo
Baldelli, Annamaria
Fedeli, Stefano Luzi
Imperatori, Luca
Laici, Gianluca
Cappelletti, Claudia
Tamburrano, Tiziana
Bracci, Raffaella
Alessandroni, Paolo

January 2020

The MILES and ELVIS studies showed that vinorelbine is one of the best options for elderly patients ...

Metronomic oral vinorelbine in previously untreated advanced non-small-cell lung cancer patients unfit for platinum-based chemotherapy: results of the randomized phase II Tempo Lung trial

Camerini, A.
Morabito, A.
Montanino, A.
Bernabé Caro, Reyes
Grossi, F.
Ramlau, R.
Ciuleanu, T. E.
Ceresoli, G. L.
Pasello, G.
de Marinis, F.
Bosch-Barrera, Joaquim
Laundreau, P.
Gautier, S.
Ta Thanh Minh, C.
Kowalski, D.

March 2022

[Background] To assess the efficacy and safety of a metronomic schedule of oral vinorelbine (mVNR) i...

Metronomic chemotherapy in non-small-cell lung cancer — current status

Knetki-Wróblewska, Magdalena
Krzakowski, Maciej

August 2016

Chemotherapy remains a standard treatment of advanced non-small-cell lung cancer. Metronomic chemoth...

Metronomic oral vinorelbine in previously untreated advanced non-small-cell lung cancer patients unfit for platinum-based chemotherapy: results of the randomized phase II Tempo Lung trial.

Camerini, A
Morabito, A
Montanino, A
Bernabé, R
Grossi, F
Ramlau, R
Ciuleanu, T-E
Ceresoli, G-L
Pasello, G
de Marinis, F
Bosch-Barrera, J
Laundreau, P
Gautier, S
Ta Thanh Minh, C
Kowalski, D

February 2021

To assess the efficacy and safety of a metronomic schedule of oral vinorelbine (mVNR) in advanced no...

Clinical outcomes of oral metronomic vinorelbine in advanced non-small cell lung cancer: correlations with pharmacokinetics and MDR1 polymorphisms

M. Gusella
F. Pasini
D. Caruso
C. Barile
Y. Modena
A. Fraccon
L. Bertolaso
D. Menon
G. Crepaldi
A. Bononi
R. Spezzano
G. Telatin
G. Corona
R. Padrini

January 2018

Purpose: This study investigated correlations of the clinical outcomes of oral metronomic vinorelbin...

Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy : the MA.NI.LA. multicenter, randomized, controlled, phase II trial

M. Platania
F. Pasini
L. Porcu
M. Boeri
F. Verderame
Y. Modena
A. Del Conte
F. Nichetti
M.C. Garassino
A. Martinetti
E. Sottotetti
L. Cavanna
E. Vattemi
D. Pozzessere
A. Bertolini
L. Irtelli
C. Verri
G. Sozzi
C. Proto
U. Pastorino
V. Torri
A.P. Fraccon
F. Spinnato
D. Signorelli
G. Lo Russo
A. Tuzi
R. Gallucci
S. Cinieri
M. Mencoboni
P. Antonelli
L. Giacomelli
F. de Braud

June 2019

BACKGROUND: Oral vinorelbine administered at the maximum tolerated dose has already showed activity...

Metronomic treatment of advanced non-small-cell lung cancer with daily oral vinorelbine - a Phase I trial

Gütz, Sylvia
Tufman, Amanda
Pawel, Joachim von
Rittmeyer, Achim
Borgmeier, Astrid
Ferre, Pierre
Edlich, Birgit
Huber, Rudolf Maria

January 2017

Micro-abstract: In a Phase I dose-finding study of metronomic daily oral vinorelbine in advanced non...

Aim of the study: The study examined

August 2016

the response rate, response duration and toxicity of vinorelbine and fluorouracil or vinorelbine alo...

Oral Vinorelbine for the Treatment of Metastatic Non-Small Cell Lung Cancer in Elderly Patients: A Phase II Trial of Efficacy and Toxicity.

Kanard, Anne
Jatoi, Aminah
Castillo, Rene
Geyer, Susan
Schulz, Thomas K
Fitch, Tom R, MD
Rowland, Kendrith M
Nair, Suresh G., MD
Krook, James E, MD
Kugler, John W, MD

March 2004

PURPOSE: Before now oral vinorelbine has not yet been tested in a cohort of elderly, advanced non-sm...

Oral vinorelbine and capecitabine as first-line therapy in metastatic breast cancer: a retrospective analysis

Valerio, MR
Spadaro, P
Arcana, C
Borsellino, N
Cipolla, C
Vigneri, P
Piazza, D
Gebbia, V

November 2021

Lay abstract The adoption of metronomic chemotherapy in the treatment of breast cancer is an importa...

Metronomic oral vinorelbine as first-line treatment in elderly (>65 year) patients with advanced NSCLC

Lumachi, Franco
Del Conte, A
Saracchini, S
Mazza, F
Ubiali, P
Basso, Smm

January 2017

Introduction: Non-small cell lung cancer (NSCLC) is one of the most frequent malignancies, and the m...

lEarly Clinical Studies Group ofEORTC, 2EORTCData Center, ^Pierre Fabre Oncology, ^Centre Oscar Lambret, Lille, France Summary

September 2016

Background: Vinorelbine is an active drug in the treatment of lung and breast cancers and has a favo...

A Randomized Phase II Trial of Single-Agent Gemcitabine, Vinorelbine, or Docetaxel in Patients with Advanced Non-small Cell Lung Cancer Who Have Poor Performance Status and/or Are Elderly

Leong, Swan Swan
Toh, Chee Keong
Lim, Wan Teck
Lin, Xu
Tan, Say Beng
Poon, Donald
Tay, Miah Hiang
Foo, Kian Fong
Ho, Juliana
Tan, Eng Huat

March 2007

Background:Patients with poor performance status and/or are elderly are frequently considered a comp...

Oral metronomic vinorelbine in advanced non-small cell lung cancer patients unfit for chemotherapy

Banna G. L.
Camerini A.
Bronte G.
Anile G.
Addeo A.
Rundo F.
Zanghi G.
Lal R.
Libra M.

January 2018

Aim: To explore the feasibility and activity of oral metronomic vinorelbine patients with advanced N...

Metronomic oral vinorelbine for the treatment of advanced non-small cell lung cancer. a multicenter international retrospective analysis

Camerini A.
Banna G. L.
Cinieri S.
Pezzuto A.
Mencoboni M.
Rosetti F.
Figueiredo A.
Rizzo P.
Ricci A.
Langenhoven L.
Santo A.
Addeo A.
Amoroso D.
Barata F.

January 2019

Purpose: Metronomic oral vinorelbine (MOV) could be a treatment option for unfit patients with advan...

Metronomic Oral Vinorelbine: An Alternative Schedule in Elderly and Patients PS2 With Local/Advanced and Metastatic NSCLC Not Oncogene-addicted

Rossi, David
Lippe, Paolo
Rocchi, Marco Bruno Luigi
Sarti, Donatella
Catalano, Vincenzo
Graziano, Francesco
Giordani, Paolo
Baldelli, Annamaria
Fedeli, Stefano Luzi
Imperatori, Luca
Laici, Gianluca
Cappelletti, Claudia
Tamburrano, Tiziana
Bracci, Raffaella
Alessandroni, Paolo

January 2020

The MILES and ELVIS studies showed that vinorelbine is one of the best options for elderly patients ...

Metronomic oral vinorelbine in previously untreated advanced non-small-cell lung cancer patients unfit for platinum-based chemotherapy: results of the randomized phase II Tempo Lung trial

Camerini, A.
Morabito, A.
Montanino, A.
Bernabé Caro, Reyes
Grossi, F.
Ramlau, R.
Ciuleanu, T. E.
Ceresoli, G. L.
Pasello, G.
de Marinis, F.
Bosch-Barrera, Joaquim
Laundreau, P.
Gautier, S.
Ta Thanh Minh, C.
Kowalski, D.

March 2022

[Background] To assess the efficacy and safety of a metronomic schedule of oral vinorelbine (mVNR) i...

Metronomic chemotherapy in non-small-cell lung cancer — current status

Knetki-Wróblewska, Magdalena
Krzakowski, Maciej

August 2016

Chemotherapy remains a standard treatment of advanced non-small-cell lung cancer. Metronomic chemoth...

Metronomic oral vinorelbine in previously untreated advanced non-small-cell lung cancer patients unfit for platinum-based chemotherapy: results of the randomized phase II Tempo Lung trial.

Camerini, A
Morabito, A
Montanino, A
Bernabé, R
Grossi, F
Ramlau, R
Ciuleanu, T-E
Ceresoli, G-L
Pasello, G
de Marinis, F
Bosch-Barrera, J
Laundreau, P
Gautier, S
Ta Thanh Minh, C
Kowalski, D

February 2021

To assess the efficacy and safety of a metronomic schedule of oral vinorelbine (mVNR) in advanced no...

Clinical outcomes of oral metronomic vinorelbine in advanced non-small cell lung cancer: correlations with pharmacokinetics and MDR1 polymorphisms

M. Gusella
F. Pasini
D. Caruso
C. Barile
Y. Modena
A. Fraccon
L. Bertolaso
D. Menon
G. Crepaldi
A. Bononi
R. Spezzano
G. Telatin
G. Corona
R. Padrini

January 2018

Purpose: This study investigated correlations of the clinical outcomes of oral metronomic vinorelbin...

Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy : the MA.NI.LA. multicenter, randomized, controlled, phase II trial

M. Platania
F. Pasini
L. Porcu
M. Boeri
F. Verderame
Y. Modena
A. Del Conte
F. Nichetti
M.C. Garassino
A. Martinetti
E. Sottotetti
L. Cavanna
E. Vattemi
D. Pozzessere
A. Bertolini
L. Irtelli
C. Verri
G. Sozzi
C. Proto
U. Pastorino
V. Torri
A.P. Fraccon
F. Spinnato
D. Signorelli
G. Lo Russo
A. Tuzi
R. Gallucci
S. Cinieri
M. Mencoboni
P. Antonelli
L. Giacomelli
F. de Braud

June 2019

BACKGROUND: Oral vinorelbine administered at the maximum tolerated dose has already showed activity...

Metronomic treatment of advanced non-small-cell lung cancer with daily oral vinorelbine - a Phase I trial

Gütz, Sylvia
Tufman, Amanda
Pawel, Joachim von
Rittmeyer, Achim
Borgmeier, Astrid
Ferre, Pierre
Edlich, Birgit
Huber, Rudolf Maria

January 2017

Micro-abstract: In a Phase I dose-finding study of metronomic daily oral vinorelbine in advanced non...

Aim of the study: The study examined

August 2016

the response rate, response duration and toxicity of vinorelbine and fluorouracil or vinorelbine alo...

Oral Vinorelbine for the Treatment of Metastatic Non-Small Cell Lung Cancer in Elderly Patients: A Phase II Trial of Efficacy and Toxicity.

Kanard, Anne
Jatoi, Aminah
Castillo, Rene
Geyer, Susan
Schulz, Thomas K
Fitch, Tom R, MD
Rowland, Kendrith M
Nair, Suresh G., MD
Krook, James E, MD
Kugler, John W, MD

March 2004

PURPOSE: Before now oral vinorelbine has not yet been tested in a cohort of elderly, advanced non-sm...

Oral vinorelbine and capecitabine as first-line therapy in metastatic breast cancer: a retrospective analysis

Valerio, MR
Spadaro, P
Arcana, C
Borsellino, N
Cipolla, C
Vigneri, P
Piazza, D
Gebbia, V

November 2021

Lay abstract The adoption of metronomic chemotherapy in the treatment of breast cancer is an importa...

Metronomic oral vinorelbine as first-line treatment in elderly (>65 year) patients with advanced NSCLC

Lumachi, Franco
Del Conte, A
Saracchini, S
Mazza, F
Ubiali, P
Basso, Smm

January 2017

Introduction: Non-small cell lung cancer (NSCLC) is one of the most frequent malignancies, and the m...

lEarly Clinical Studies Group ofEORTC, 2EORTCData Center, ^Pierre Fabre Oncology, ^Centre Oscar Lambret, Lille, France Summary

September 2016

Background: Vinorelbine is an active drug in the treatment of lung and breast cancers and has a favo...

A Randomized Phase II Trial of Single-Agent Gemcitabine, Vinorelbine, or Docetaxel in Patients with Advanced Non-small Cell Lung Cancer Who Have Poor Performance Status and/or Are Elderly

Leong, Swan Swan
Toh, Chee Keong
Lim, Wan Teck
Lin, Xu
Tan, Say Beng
Poon, Donald
Tay, Miah Hiang
Foo, Kian Fong
Ho, Juliana
Tan, Eng Huat

March 2007

Background:Patients with poor performance status and/or are elderly are frequently considered a comp...

Oral metronomic vinorelbine in advanced non-small cell lung cancer patients unfit for chemotherapy

Banna G. L.
Camerini A.
Bronte G.
Anile G.
Addeo A.
Rundo F.
Zanghi G.
Lal R.
Libra M.

January 2018

Aim: To explore the feasibility and activity of oral metronomic vinorelbine patients with advanced N...

An individual patient-data meta-analysis of metronomic oral vinorelbine in metastatic non-small cell lung cancer

Abstract

Extracted data

An individual patient-data meta-analysis of metronomic oral vinorelbine in metastatic non-small cell lung cancer

Abstract

Extracted data

Related items

Related items